HRMY - Insider Activity Update: Jeffrey Dierks Executes Options Exercise Resulting In $279K At Harmony Biosciences | Benzinga
Jeffrey Dierks, Chief Commercial Officer at Harmony Biosciences (NASDAQ:HRMY), reported a large exercise of company stock options on March 18, according to a new SEC filing.
What Happened: Disclosed in a Form 4 filing on Monday with the U.S. Securities and Exchange Commission, Dierks, Chief Commercial Officer at Harmony Biosciences, executed a strategic derivative sale. This involved exercising stock options for 11,979 shares of HRMY, resulting in a transaction value of $279,949.
During Tuesday's morning session, Harmony Biosciences shares down by 0.0%, currently priced at $31.59. Considering the current price, Dierks's 11,979 shares have a total value of $279,949.
Discovering Harmony Biosciences: A Closer Look
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
A Deep Dive into Harmony Biosciences's Financials
Revenue Growth: Harmony Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid ...